AMRI Promotes Two Company Executives to Key Positions
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Albany Molecular Research (AMRI) Updates FY15 Guidance Following Gadea Pharma Acquisition
September 15, 2015 7:04 AM EDTFollowing the acquisition of Gadea Pharmaceutical Group, AMRI (Nasdaq: AMRI) has updated guidance for full year 2015.
"We are very pleased to provide our updated outlook for 2015 results which reflect the recent addition of Gadea Pharmaceutical Group," said William S. Marth, AMRI's president and chief executive officer. "Gadea brought us over 90 technically complex API programs, greatly enhancing our commercial portfolio and opportunities for expanded business. With Gadea's strong EBITDA and margins, combined with our expanding base business, we remain confident in our outlook which includes full year contract revenue growth of over 50%... More
